[Antiretrovirals].
Teruya
Katsuji
K
International Medical Center of Japan, AIDS Clinical Center.
Oka
Shinichi
S
D000140:Acidosis, Lactic / Q000139:chemically induced; D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D016049:Didanosine / Q000008:administration & dosage / Q000009:adverse effects; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D039682:HIV-Associated Lipodystrophy Syndrome / Q000139:chemically induced; D006467:Hemophilia A; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D019469:Indinavir; D019829:Nevirapine / Q000008:administration & dosage / Q000009:adverse effects; D010078:Oxazines / Q000008:administration & dosage / Q000009:adverse effects; D018894:Reverse Transcriptase Inhibitors; D018119:Stavudine / Q000008:administration & dosage / Q000009:adverse effects; D015215:Zidovudine / Q000008:administration & dosage / Q000009:adverse effects
D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D017320:HIV Protease Inhibitors; D010078:Oxazines; D018894:Reverse Transcriptase Inhibitors; D015215:Zidovudine; D019469:Indinavir; D019829:Nevirapine; D018119:Stavudine; C098320:efavirenz; D016049:Didanosine